Chong Kun Dang Pharmaceutical
Clinical trials sponsored by Chong Kun Dang Pharmaceutical, explained in plain language.
-
New drug combo for BRCA ovarian cancer enters early testing
Disease control Not yet recruitingThis early-stage study tests two drugs, CKD-215 and D215, in 24 adults aged 19-75 with advanced BRCA-mutated ovarian, fallopian tube, or primary peritoneal cancer. The goal is to compare how the body processes each drug and check for side effects. Participants will receive both d…
Phase: PHASE1 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New combo therapy aims to control diabetes without side effects
Disease control Not yet recruitingThis study compares two different drug combinations for people with type 2 diabetes whose blood sugar is not well controlled with metformin and sitagliptin. About 200 adults will receive either empagliflozin or glimepiride added to their current treatment. The goal is to see whic…
Phase: PHASE4 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC